Etanercept biosimilar - Coherus Biosciences/Daiichi Sankyo

Drug Profile

Etanercept biosimilar - Coherus Biosciences/Daiichi Sankyo

Alternative Names: BAX 2200; CHS-0214

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus Biosciences; Daiichi Sankyo Company
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 27 Sep 2016 Etanercept biosimilar is no longer licensed to Shire
  • 09 Aug 2016 Coherus Biosciences completes enrolment in two phase I bridging trials
  • 08 Aug 2016 Coherus Biosciences initiates enrolment in a phase I bridging trial before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top